Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice.
Zool Res
; 42(5): 633-636, 2021 Sep 18.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1369995
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the global coronavirus disease 2019 (COVID-19) pandemic. Numerous studies have demonstrated that cardiovascular disease may affect COVID-19 progression. In the present study, we investigated the effect of hypertension on viral replication and COVID-19 progression using a hypertensive mouse model infected with SARS-CoV-2. Results revealed that SARS-CoV-2 replication was delayed in hypertensive mouse lungs. In contrast, SARS-CoV-2 replication in hypertensive mice treated with the antihypertensive drug captopril demonstrated similar virus replication as SARS-CoV-2-infected normotensive mice. Furthermore, antihypertensive treatment alleviated lung inflammation induced by SARS-CoV-2 replication (interleukin (IL)-1ß up-regulation and increased immune cell infiltration). No differences in lung inflammation were observed between the SARS-CoV-2-infected normotensive mice and hypertensive mice. Our findings suggest that captopril treatment may alleviate COVID-19 progression but not affect viral replication.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Captopril
/
SARS-CoV-2
/
COVID-19
/
Hipertensión
/
Enfermedades Pulmonares
/
Antihipertensivos
Tipo de estudio:
Estudio de etiologia
Tópicos:
Covid persistente
Límite:
Animales
Idioma:
Inglés
Revista:
Zool Res
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
J.issn.2095-8137.2021.206
Similares
MEDLINE
...
LILACS
LIS